Shandong Sihuan Pharmaceutical Co., Ltd. is a national high-tech enterprise engaged in the research and development, production and sales of new drugs. It was registered in 2010 with a registered capital of 40 million. The factory is located in Pingyuan County, Dezhou City, and the R&D center is located in Jinan High-tech Zone. The products involved include antibiotic drugs, cardiovascular drugs, diabetes drugs and anti-tumor drugs.



LOCATION : Home - About Us

1. Overview of business management
In terms of corporate management, the company continued to increase its investment in environmental protection. From 2018 to 2019, it invested 4 million yuan in the upgrading and transformation of environmental protection equipment, and passed the dual-system acceptance safely; the work site implemented 6S site management. The company will strengthen internal control construction, strengthen financial control, and demand benefits from management, and use amoeba to improve the company's unit efficiency; the company will establish a subsidiary in Hechi, Guangxi, a production branch in Jining, and a new production workshop to increase the company's output value; The company purchased real estate in Jinan Yinfeng Biological City and established Shandong Sihuan Jinan branch to actively research and develop new drugs to enhance the company's technological competitive advantage. In 2017, it was listed on the Qilu Equity Exchange Center (equity code 301926), further regulating the enterprise and increasing the success rate of financing. In terms of sales, increase domestic and foreign sales revenue and increase export volume.


2. The company’s main products
The company’s products cover antibiotic drugs (cefometoxime, cefazerone, cefpirin), cardiovascular drugs (LCZ696), diabetes drugs (alogliptin, troxagliptin, linagliptin) and anti-tumor drugs Medication (Ibrutinib, Barictinib, Tofacitinib), etc. The company's products are mainly exported to South Korea, India and other countries. 

The company has its own unique advantages in the development of pharmaceutical raw materials and intermediate production processes. The preparation method provided by the authorized invention patent "a preparation method of troxagliptin" has mild reaction conditions, high conversion rate, less impurities, low cost, and high purity of the finished product, which is more suitable for industrial production. The invention patent "a method for preparing cefmenoxime hydrochloride" has cheap and easy raw materials, high product purity and high yield, which is beneficial to the realization of industrial production.


3. Basic situation of enterprise innovation

The company's antibiotic drugs and diabetes drug research and development level ranks among the most advanced in China. The research and development team includes more than 30 Ph.Ds, masters and basic talents. It also hires Professor Hou Zhaosheng from Shandong Normal University as a technical consultant. A well-known company with several years of drug research and development experience Experts specifically guide technology research and development and production. The company entered the database of technology-based small, medium and micro enterprises in 2016, and was awarded the "Advanced Unit of Scientific and Technological Innovation" by the Pingyuan County Party Committee for three consecutive years in 2016-2018. In July 2017, it was awarded the "Dezhou High-tech Enterprise" by the Dezhou Science and Technology Bureau. In December 2017, it passed the "One Enterprise One Technology" of Dezhou City, and in October 2018 it was awarded the Shandong Province "Specialized and Special New" SMEs. In November 2018, it passed the "National High-tech Enterprise" and in December 2018 it passed the "Dezhou City" Anti-diabetic Drug Engineering Technology Research Center". In April 2019, Shandong Provincial Department of Science and Technology awarded the enterprise "Technology SMEs"


4. Basic situation of enterprise system construction
The company has passed ISO9001 quality system certification, and has established an intellectual property protection system and an enterprise production safety protection system. The amoeba operating accounting of "6S site management" and sub-sector accounting was implemented. And passed the safety double system acceptance and implementation.